About this trial
clinical evaluation of the prevalence and severity of cognitive impairment among patients after ischemic and haemorrhagic stroke admitted to the Neuropsychiatry department
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
Age above 60 years, refusal to participate in the study, pre-existing dementia or significant psychiatric illness, severe aphasia or communication deficits precluding cognitive testing or severe comorbid condition limiting follow-ups, systemic diseases that are known to affect the central nervous system, such as (thyroid dysfunction, chronic infections, or system failure like liver or renal failure), significant sensory impairment (deafness and blindness), history of malignancy and those who have had neurosurgical procedures or severe head trauma at any time before a stroke.
Trial population
egyptian population
Trial design
Cohort
Prospective
Treatments tested in this trial
Cognitive assessment: Montreal Cognitive Assessment (MoCA), Cognitive Assessment for Stroke patients, Oxford cognitive screening, Trail Making Test B, Digit Span-Backward, verbal fluency, Clinical Dem
Other interventionFollow-up: for cognitive and functional reassessment
Treatment groups
Trial outcomes
Primary outcomes
the prevalence of cognitive impairment among patients after ischemic and haemorrhagic stroke admitted to the Neuropsychiatry department
clinical evaluation of the prevalence of cognitive impairment among patients after ischemic and haemorrhagic stroke admitted to the Neuropsychiatry departmen
prevalence estimates of PSCI within the stroke population admitted to a tertiary hospital.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: